RPS2

Small ribosomal subunit protein uS5 · P15880 · RPS2 on Sugi Atlas →

3,677 patent compounds predicted against RPS2, 1,927 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPS2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC	PHASE2	COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	PHASE1	WITHDRAWN
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care	nan	COMPLETED
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)	nan	RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Natural History and Genetic Studies of Usher Syndrome	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Genetic Analysis of Gray Platelet Syndrome	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC	nan	UNKNOWN
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer	nan	UNKNOWN
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a RPS2 binder may also engage these)

Protein	Name	Similarity
P27952	—	1.000	P27952 →
P25444	—	1.000	P25444 →
O18789	—	1.000	O18789 →
Q93VB8	—	1.000	Q93VB8 →
Q9SCM3	—	1.000	Q9SCM3 →
P25443	—	1.000	P25443 →
P51403	—	1.000	P51403 →
Q8L8Y0	—	1.000	Q8L8Y0 →
G1SWM1	—	1.000	G1SWM1 →
P49688	—	0.999	P49688 →
P49154	—	0.999	P49154 →
O43992	—	0.998	O43992 →
P31009	—	0.998	P31009 →
O74892	—	0.997	O74892 →
P27685	—	0.997	P27685 →
Q90YS3	—	0.997	Q90YS3 →
Q5A900	—	0.996	Q5A900 →
Q1GPB6	—	0.989	Q1GPB6 →
C0ZW43	—	0.988	C0ZW43 →
C1AL55	—	0.987	C1AL55 →
Q93425	—	0.987	Q93425 →
Q9RSL1	—	0.987	Q9RSL1 →
P66575	—	0.987	P66575 →
Q318K0	—	0.987	Q318K0 →
A1A086	—	0.987	A1A086 →
A1KGK2	—	0.987	A1KGK2 →
Q6NJ85	—	0.987	Q6NJ85 →
A8G745	—	0.986	A8G745 →
A5IYW9	—	0.986	A5IYW9 →
Q5NQ48	—	0.986	Q5NQ48 →